MA08.09 Clinical Management of Lung Adenocarcinoma Patients With HER2 V659E Mutation
Ziqi Jia(Chinese Academy of Medical Sciences & Peking Union Medical College), Naixin Liang(Chinese Academy of Medical Sciences & Peking Union Medical College), Feng Peng(Chinese Academy of Sciences), Lee‐Lun Lai(KTH Royal Institute of Technology), Han Han‐Zhang(Burning Rock Biotech (China)), Songling Ma, Shenpeng Ying(Taizhou Central Hospital), Yiting Wang(Second Affiliated Hospital of Jilin University), Yi Lü(Shanghai University of Traditional Chinese Medicine), Pengju Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaolan Zhang(Qingdao University), Feng Chen(Hainan General Hospital), B. Li(Burning Rock Biotech (China)), Xudong Chen(Hangzhou First People's Hospital), Jing Zhao(BGI Group (China)), Caihong Ma, Y. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Siwei Zhang(Anyang Tumor Hospital), D. Wu(Shaoxing People's Hospital), W. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), J. Ye(Burning Rock Biotech (China))
Cited by 0
Related Papers
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020
|Cancer Communications|2021|1.1k
Cancer registration in China and its role in cancer prevention and control
|The Lancet Oncology|2020|501